Pure Global
NCT05304949

Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity

Regulatory Post-Marketing Surveillance(PMS) Study for Lucentis®(Ranibizumab) in Patients With Retinopathy of Prematurity
Novartis Pharmaceuticals·ClinicalTrials.gov·otherRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Retinopathy of Prematurity
Drug/Device/Intervention
Lucentis
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Novartis Pharmaceuticals
Funder
Novartis
Location
Daegu, South Korea
Timeline & enrollment
Phase
N/A
Start date
Jun 22, 2022
End date
Jan 12, 2025
Enrollment
60 participants
Primary outcome

Incidence of adverse events/adverse drug reactions

Summary

This study is an open-labeled, multicenter, single arm, observational post-marketing
 surveillance study under routine clinical practice with no mandated treatments, visits or
 assessments.

ICD-10 classifications
Retinopathy of prematurityOther proliferative retinopathyBackground retinopathy and retinal vascular changesDiabetic retinopathyRetinal disorder, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05304949
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05304949 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Pharmaceuticals and is currently Recruiting. The study focuses on Retinopathy of Prematurity. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.